Long-term control of mycosis fungoides of the hands with topical bexarotene

International Journal of Dermatology

Volumn 42, Issue 3, 2003, Pages 238-241

  Lain, Ted ^a   Talpur, Rakhshandra ^a   Duvic, Madeleine ^a,b,c,d  

^a University of Texas Health Science Center at Houston   (United States)

^b Department of Dermatology ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CLOBETASOL; ANTINEOPLASTIC AGENT; TETRALIN DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; CANCER CONTROL; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; GENE REARRANGEMENT; HUMAN; IN SITU HYBRIDIZATION; MALE; MYCOSIS FUNGOIDES; PUVA; SKIN BIOPSY; SKIN EXAMINATION; SKIN IRRITATION; HAND; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SKIN; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANTICARCINOGENIC AGENTS; HAND; HUMANS; MALE; MYCOSIS FUNGOIDES; SKIN; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 0038207680     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2003.01782.x     Document Type: Article

References (14)

1. 238-241 1 Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Sem Oncol 1999;26:276-289.
2. Kaye F, Bunn P, Steinberg S. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the treatment of mycosis fungoides. N Engl J Med 1989;321:1784-1790.
3. Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40: 418-425.
4. Kim YH, Chow S, Varghese A, et al. Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 1999;135: 26-32.
5. Breneman D, Duvic M, Kuzel T, et al. Phase I-II trial of bexarotene gel (Targretin®) for the skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch. Dermatol 2002, Maic; 138(3):325-32.
6. Cohen MH, Hirschfeld S, Flamm Honig S, et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001;6(1): 4-11.
7. Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. Arch Dermatol 1996;132:1309-1313.
8. Apisarnthanarax, N, Duvic, M. Therapy options in cutaneous T-cell lymphoma: expert review. Anticancer Ther 2001; I(3):89-106.
9. Vonderheid EC, Tan ET, Kantor EF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma.J Am Acad Dermatol 1989;20: 416-420.
10. Boehm MF, Heyman RA, Nagpal S. A new generation of retinoid drugs for the treatment of dermatological diseases. Emerging Drugs 1997;2:187-303.
11. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001;10:2456-2471.
12. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin®capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-593.
13. Breneman D, Duvic M, Kuzel T, et al. Efficacy and safety of bexarotene gel in patients with previously untreated CTCL [P2o4]. Proceedings of the 59th Annual Meeting American Academy of Dermatology, Washington D.C., March 2-7, 2001.
14. Prince HM, McCormack C, Ryan G, et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: Results of the Australian patients treated on phase II trials. Anstralas J Dermatol 2001;42:91-97.